Cargando…

Tumor necrosis is an underappreciated histopathologic factor in the grading of chondrosarcoma

BACKGROUND: Cartilaginous neoplasms can be challenging to grade; there is a need to create an evidence-based rubric for grading. The goal of this study was to identify histopathologic features of chondrosarcoma that were associated with 5-year survival and to compare these to traditional patient, tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazarides, Alexander L., Abar, Bijan, Leckey, Bruce, Martin, John T., Kliassov, Evelyna G., Brigman, Brian E., Eward, William C., Cardona, Diana M., Visgauss, Julia D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288799/
https://www.ncbi.nlm.nih.gov/pubmed/37353743
http://dx.doi.org/10.1186/s12885-023-11022-x
_version_ 1785062148097966080
author Lazarides, Alexander L.
Abar, Bijan
Leckey, Bruce
Martin, John T.
Kliassov, Evelyna G.
Brigman, Brian E.
Eward, William C.
Cardona, Diana M.
Visgauss, Julia D.
author_facet Lazarides, Alexander L.
Abar, Bijan
Leckey, Bruce
Martin, John T.
Kliassov, Evelyna G.
Brigman, Brian E.
Eward, William C.
Cardona, Diana M.
Visgauss, Julia D.
author_sort Lazarides, Alexander L.
collection PubMed
description BACKGROUND: Cartilaginous neoplasms can be challenging to grade; there is a need to create an evidence-based rubric for grading. The goal of this study was to identify histopathologic features of chondrosarcoma that were associated with 5-year survival and to compare these to traditional patient, tumor and treatment variables. METHODS: This was a retrospective review of all patients undergoing surgical resection of a primary chondrosarcoma with at least 2 years of follow up. All specimens were independently reviewed by two pathologists and histopathologic features scored. Univariate and multivariate analyses were performed utilizing Kaplan Meier and proportional hazards methods to identify variables associated with 5-year disease specific survival (DSS) and disease free survival (DFS). RESULTS: We identified 51 patients with an average follow up of 49 months eligible for inclusion. 30% of tumors were low grade, 45% were intermediate grade, and 25% were high grade. In a univariate analysis considering histopathologic factors, higher tumor mitotic rate (HR 8.9, p < 0.001), tumor dedifferentiation (HR 7.3, p < 0.001), increased tumor cellularity (HR 5.8, p = 0.001), increased tumor atypia (HR 5.8, p = 0.001), LVI (HR 4.7, p = 0.04) and higher tumor necrosis (HR 3.7, p = 0.02) were all associated with worse 5-year DSS. In a multivariate analysis controlling for potentially confounding variables, higher tumor necrosis was significantly associated with disease specific survival survival (HR 3.58, p = 0.035); none of the factors were associated with DFS. CONCLUSIONS: This study provides an evidence-based means for considering histopathologic markers and their association with prognosis in chondrosarcoma. Our findings suggest that necrosis and LVI warrant further study.
format Online
Article
Text
id pubmed-10288799
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102887992023-06-24 Tumor necrosis is an underappreciated histopathologic factor in the grading of chondrosarcoma Lazarides, Alexander L. Abar, Bijan Leckey, Bruce Martin, John T. Kliassov, Evelyna G. Brigman, Brian E. Eward, William C. Cardona, Diana M. Visgauss, Julia D. BMC Cancer Research BACKGROUND: Cartilaginous neoplasms can be challenging to grade; there is a need to create an evidence-based rubric for grading. The goal of this study was to identify histopathologic features of chondrosarcoma that were associated with 5-year survival and to compare these to traditional patient, tumor and treatment variables. METHODS: This was a retrospective review of all patients undergoing surgical resection of a primary chondrosarcoma with at least 2 years of follow up. All specimens were independently reviewed by two pathologists and histopathologic features scored. Univariate and multivariate analyses were performed utilizing Kaplan Meier and proportional hazards methods to identify variables associated with 5-year disease specific survival (DSS) and disease free survival (DFS). RESULTS: We identified 51 patients with an average follow up of 49 months eligible for inclusion. 30% of tumors were low grade, 45% were intermediate grade, and 25% were high grade. In a univariate analysis considering histopathologic factors, higher tumor mitotic rate (HR 8.9, p < 0.001), tumor dedifferentiation (HR 7.3, p < 0.001), increased tumor cellularity (HR 5.8, p = 0.001), increased tumor atypia (HR 5.8, p = 0.001), LVI (HR 4.7, p = 0.04) and higher tumor necrosis (HR 3.7, p = 0.02) were all associated with worse 5-year DSS. In a multivariate analysis controlling for potentially confounding variables, higher tumor necrosis was significantly associated with disease specific survival survival (HR 3.58, p = 0.035); none of the factors were associated with DFS. CONCLUSIONS: This study provides an evidence-based means for considering histopathologic markers and their association with prognosis in chondrosarcoma. Our findings suggest that necrosis and LVI warrant further study. BioMed Central 2023-06-23 /pmc/articles/PMC10288799/ /pubmed/37353743 http://dx.doi.org/10.1186/s12885-023-11022-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lazarides, Alexander L.
Abar, Bijan
Leckey, Bruce
Martin, John T.
Kliassov, Evelyna G.
Brigman, Brian E.
Eward, William C.
Cardona, Diana M.
Visgauss, Julia D.
Tumor necrosis is an underappreciated histopathologic factor in the grading of chondrosarcoma
title Tumor necrosis is an underappreciated histopathologic factor in the grading of chondrosarcoma
title_full Tumor necrosis is an underappreciated histopathologic factor in the grading of chondrosarcoma
title_fullStr Tumor necrosis is an underappreciated histopathologic factor in the grading of chondrosarcoma
title_full_unstemmed Tumor necrosis is an underappreciated histopathologic factor in the grading of chondrosarcoma
title_short Tumor necrosis is an underappreciated histopathologic factor in the grading of chondrosarcoma
title_sort tumor necrosis is an underappreciated histopathologic factor in the grading of chondrosarcoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288799/
https://www.ncbi.nlm.nih.gov/pubmed/37353743
http://dx.doi.org/10.1186/s12885-023-11022-x
work_keys_str_mv AT lazaridesalexanderl tumornecrosisisanunderappreciatedhistopathologicfactorinthegradingofchondrosarcoma
AT abarbijan tumornecrosisisanunderappreciatedhistopathologicfactorinthegradingofchondrosarcoma
AT leckeybruce tumornecrosisisanunderappreciatedhistopathologicfactorinthegradingofchondrosarcoma
AT martinjohnt tumornecrosisisanunderappreciatedhistopathologicfactorinthegradingofchondrosarcoma
AT kliassovevelynag tumornecrosisisanunderappreciatedhistopathologicfactorinthegradingofchondrosarcoma
AT brigmanbriane tumornecrosisisanunderappreciatedhistopathologicfactorinthegradingofchondrosarcoma
AT ewardwilliamc tumornecrosisisanunderappreciatedhistopathologicfactorinthegradingofchondrosarcoma
AT cardonadianam tumornecrosisisanunderappreciatedhistopathologicfactorinthegradingofchondrosarcoma
AT visgaussjuliad tumornecrosisisanunderappreciatedhistopathologicfactorinthegradingofchondrosarcoma